U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C10H20N2S4
Molecular Weight 296.539
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DISULFIRAM

SMILES

CCN(CC)C(=S)SSC(=S)N(CC)CC

InChI

InChIKey=AUZONCFQVSMFAP-UHFFFAOYSA-N
InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/disulfiram.html

Disulfiram is a carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. Disulfiram blocks the oxidation of alcohol at the acetaldehyde stage during alcohol metabolism following disulfiram intake causing an accumulation of acetaldehyde in the blood producing highly unpleasant symptoms. Disulfiram blocks the oxidation of alcohol through its irreversible inactivation of aldehyde dehydrogenase, which acts in the second step of ethanol utilization. In addition, disulfiram competitively binds and inhibits the peripheral benzodiazepine receptor, which may indicate some value in the treatment of the symptoms of alcohol withdrawal, however this activity has not been extensively studied. Used for the treatment and management of chronic alcoholism.

CNS Activity

Originator

Approval Year

1951
105
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8146
Inhibitor
8146
 3.3 µM [IC50]
Inhibitor
8146
 101.0 µM [IC50]
Inhibitor
8146
 4.6 µM [IC50]
Inhibitor
8146
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8307
Disulfiram

Approved Use

Disulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage.

Launch Date

3.54758394E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.3 nM
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/1471547
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DISULFIRAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
7.3 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/1471547
500 mg single, oral
dose: 500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DISULFIRAM plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
7 g single, oral
Overdose
Dose: 7 g
Route: oral
Route: single
Dose: 7 g
Co-administed with::
Alcohol
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
unhealthy, 24
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 24
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
Disc. AE: Drowsiness, Flushing...
AEs leading to
discontinuation/dose reduction:
Drowsiness
Flushing
Vomiting
Coma
Hypotension
Sinus tachycardia
Arrhythmia
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
37.5 g single, oral
Overdose
Dose: 37.5 g
Route: oral
Route: single
Dose: 37.5 g
Co-administed with::
diazepam, p.o(50 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
unhealthy, 42
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 42
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
Disc. AE: Somnolence, Nightmares...
AEs leading to
discontinuation/dose reduction:
Somnolence
Nightmares
Auditory hallucinations
Tremor
Dysphagia
Dysarthria
Polyneuropathy
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
1500 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 45
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
Disc. AE: Confusion, Lethargy...
AEs leading to
discontinuation/dose reduction:
Confusion
Lethargy
Coma
Intellectual disability
Cognitive impairment
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
1000 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Co-administed with::
temozolomide(150–200 mg/m2 daily on days 1–5 of every 28 day cycle)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
unhealthy, 57
n = 5
Health Status: unhealthy
Condition: Glioblastoma
Age Group: 57
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
DLT: Delirium...
Disc. AE: Ataxia...
Dose limiting toxicities:
Delirium (grade 3, 40%)
AEs leading to
discontinuation/dose reduction:
Ataxia (grade 2-3, 40%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
500 mg 1 times / day multiple, oral
MTD
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Co-administed with::
temozolomide(150–200 mg/m2 daily on days 1–5 of every 28 day cycle)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
unhealthy, 57
n = 7
Health Status: unhealthy
Condition: Glioblastoma
Age Group: 57
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
Disc. AE: Delirium...
AEs leading to
discontinuation/dose reduction:
Delirium (grade 3, 14.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
250 mg 1 times / day multiple, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: Cocaine dependence
Age Group: adult
Population Size: 28
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
Other AEs: Drowsiness, Fatigue...
Other AEs:
Drowsiness (below serious, 5 patients)
Fatigue (below serious, 3 patients)
Restlessness (below serious, 4 patients)
Headache (below serious, 5 patients)
Optic neuritis (below serious, 1 patient)
Nausea and vomiting (below serious, 5 patients)
Rash (below serious, 2 patients)
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
AEs

AEs

AESignificanceDosePopulation
Arrhythmia Disc. AE
7 g single, oral
Overdose
Dose: 7 g
Route: oral
Route: single
Dose: 7 g
Co-administed with::
Alcohol
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
unhealthy, 24
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 24
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
Coma Disc. AE
7 g single, oral
Overdose
Dose: 7 g
Route: oral
Route: single
Dose: 7 g
Co-administed with::
Alcohol
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
unhealthy, 24
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 24
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
Drowsiness Disc. AE
7 g single, oral
Overdose
Dose: 7 g
Route: oral
Route: single
Dose: 7 g
Co-administed with::
Alcohol
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
unhealthy, 24
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 24
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
Flushing Disc. AE
7 g single, oral
Overdose
Dose: 7 g
Route: oral
Route: single
Dose: 7 g
Co-administed with::
Alcohol
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
unhealthy, 24
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 24
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
Hypotension Disc. AE
7 g single, oral
Overdose
Dose: 7 g
Route: oral
Route: single
Dose: 7 g
Co-administed with::
Alcohol
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
unhealthy, 24
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 24
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
Sinus tachycardia Disc. AE
7 g single, oral
Overdose
Dose: 7 g
Route: oral
Route: single
Dose: 7 g
Co-administed with::
Alcohol
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
unhealthy, 24
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 24
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
Vomiting Disc. AE
7 g single, oral
Overdose
Dose: 7 g
Route: oral
Route: single
Dose: 7 g
Co-administed with::
Alcohol
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
unhealthy, 24
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 24
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/7421263
Page: p.741
Auditory hallucinations Disc. AE
37.5 g single, oral
Overdose
Dose: 37.5 g
Route: oral
Route: single
Dose: 37.5 g
Co-administed with::
diazepam, p.o(50 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
unhealthy, 42
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 42
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
Dysarthria Disc. AE
37.5 g single, oral
Overdose
Dose: 37.5 g
Route: oral
Route: single
Dose: 37.5 g
Co-administed with::
diazepam, p.o(50 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
unhealthy, 42
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 42
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
Dysphagia Disc. AE
37.5 g single, oral
Overdose
Dose: 37.5 g
Route: oral
Route: single
Dose: 37.5 g
Co-administed with::
diazepam, p.o(50 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
unhealthy, 42
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 42
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
Nightmares Disc. AE
37.5 g single, oral
Overdose
Dose: 37.5 g
Route: oral
Route: single
Dose: 37.5 g
Co-administed with::
diazepam, p.o(50 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
unhealthy, 42
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 42
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
Polyneuropathy Disc. AE
37.5 g single, oral
Overdose
Dose: 37.5 g
Route: oral
Route: single
Dose: 37.5 g
Co-administed with::
diazepam, p.o(50 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
unhealthy, 42
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 42
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
Somnolence Disc. AE
37.5 g single, oral
Overdose
Dose: 37.5 g
Route: oral
Route: single
Dose: 37.5 g
Co-administed with::
diazepam, p.o(50 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
unhealthy, 42
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 42
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
Tremor Disc. AE
37.5 g single, oral
Overdose
Dose: 37.5 g
Route: oral
Route: single
Dose: 37.5 g
Co-administed with::
diazepam, p.o(50 mg, single)
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
unhealthy, 42
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 42
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/1431956
Page: p.925
Cognitive impairment Disc. AE
1500 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 45
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
Coma Disc. AE
1500 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 45
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
Confusion Disc. AE
1500 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 45
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
Intellectual disability Disc. AE
1500 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 45
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
Lethargy Disc. AE
1500 mg 1 times / day multiple, oral (max)
Overdose
Dose: 1500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1500 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
unhealthy, 45
n = 1
Health Status: unhealthy
Condition: Alcoholism
Age Group: 45
Sex: M
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/8341040
Page: p.390
Ataxia grade 2-3, 40%
Disc. AE
1000 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Co-administed with::
temozolomide(150–200 mg/m2 daily on days 1–5 of every 28 day cycle)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
unhealthy, 57
n = 5
Health Status: unhealthy
Condition: Glioblastoma
Age Group: 57
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
Delirium grade 3, 40%
DLT, Disc. AE
1000 mg 1 times / day multiple, oral
Highest studied dose
Dose: 1000 mg, 1 times / day
Route: oral
Route: multiple
Dose: 1000 mg, 1 times / day
Co-administed with::
temozolomide(150–200 mg/m2 daily on days 1–5 of every 28 day cycle)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
unhealthy, 57
n = 5
Health Status: unhealthy
Condition: Glioblastoma
Age Group: 57
Sex: M+F
Population Size: 5
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
Delirium grade 3, 14.3%
Disc. AE
500 mg 1 times / day multiple, oral
MTD
Dose: 500 mg, 1 times / day
Route: oral
Route: multiple
Dose: 500 mg, 1 times / day
Co-administed with::
temozolomide(150–200 mg/m2 daily on days 1–5 of every 28 day cycle)
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
unhealthy, 57
n = 7
Health Status: unhealthy
Condition: Glioblastoma
Age Group: 57
Sex: M+F
Population Size: 7
Sources:
https://pubmed.ncbi.nlm.nih.gov/26966095
Page: p.4,5
Optic neuritis below serious, 1 patient
250 mg 1 times / day multiple, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: Cocaine dependence
Age Group: adult
Population Size: 28
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
Rash below serious, 2 patients
250 mg 1 times / day multiple, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: Cocaine dependence
Age Group: adult
Population Size: 28
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
Fatigue below serious, 3 patients
250 mg 1 times / day multiple, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: Cocaine dependence
Age Group: adult
Population Size: 28
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
Restlessness below serious, 4 patients
250 mg 1 times / day multiple, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: Cocaine dependence
Age Group: adult
Population Size: 28
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
Drowsiness below serious, 5 patients
250 mg 1 times / day multiple, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: Cocaine dependence
Age Group: adult
Population Size: 28
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
Headache below serious, 5 patients
250 mg 1 times / day multiple, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: Cocaine dependence
Age Group: adult
Population Size: 28
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
Nausea and vomiting below serious, 5 patients
250 mg 1 times / day multiple, oral
Dose: 250 mg, 1 times / day
Route: oral
Route: multiple
Dose: 250 mg, 1 times / day
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
unhealthy, adult
n = 28
Health Status: unhealthy
Condition: Cocaine dependence
Age Group: adult
Population Size: 28
Sources:
https://clinicaltrials.gov/ct2/show/NCT00350870
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1532
inhibitor
1695
inhibitor
1789

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2E1
846

CYP2C19
1410
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP2C19
1484
 no
no (co-administration study)
Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo
CYP2C9
1747
 no
no (co-administration study)
Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo
CYP2D6
1826
 no
no (co-administration study)
Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo
CYP3A4
1857
 no
no (co-administration study)
Comment: Results show that single-dose disulfiram does not cause clinically significant inhibition of human CYP2C9, 2C19, 2D6, and 3A4 activities in vivo
CYP2E1
929
 yes [Ki 12.1 uM]
DCC
1
CYP2E1
929
 yes
yes (co-administration study)
Comment: Disulfiram, a selective inhibitor of human hepatic P450 2E1, prevented 80-90% of isoflurane metabolism
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:4659
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4659
ChemicalBook
CB0476519
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0476519
MolPort
MolPort-001-792-519
https://www.molport.com/shop/molecule-link/MolPort-001-792-519
Selleck Chemicals
Disulfiram(Antabuse)
http://www.selleckchem.com/products/Disulfiram(Antabuse).html
ZINC
ZINC000001529266
http://zinc15.docking.org/substances/ZINC000001529266
eMolecules
28294932
https://www.emolecules.com/cgi-bin/more?vid=28294932
eMolecules
531942
https://www.emolecules.com/cgi-bin/more?vid=531942
PubMed

PubMed

TitleDatePubMed
Catecholamine correlates of isolation-induced aggression in mice.
1975 Mar
[Disulfiram neuropathy].
1992 Aug 21
Disulfiram toxicity and catatonia in a forensic outpatient.
1992 Sep
Psychosis with disulfiram prescribed under probation order.
1992 Sep 26
Acetaldehyde prevents nuclear factor-kappa B activation and hepatic inflammation in ethanol-fed rats.
1999 Jul
Disulfiram and buprenorphine for treating cocaine addiction.
2000 Jul
One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment.
2000 Sep
Effect of enzyme inhibitors on protein quaternary structure determined by on-line size exclusion chromatography-microelectrospray ionization mass spectrometry.
2001 Jan
In vivo inhibition of aldehyde dehydrogenase by disulfiram.
2001 Jan 30
The URICA as a measure of motivation to change among treatment-seeking individuals with concurrent alcohol and cocaine problems.
2002 Dec
[Disulfiram neuropathy. Report of 3 cases].
2002 Sep
Molecular mechanism for activation of superoxide-producing NADPH oxidases.
2003 Dec 31
Acute solvent exposure induced activation of cytochrome P4502E1 causes proximal tubular cell necrosis by oxidative stress.
2003 Jun
The role of Antabuse (disulfiram) in the treatment of alcohol use problems.
2003 May-Jun
[Acute higher funghi mushroom poisoning and its treatment].
2003 Sep 20
Changes in plasma membrane Ca2+ -ATPase expression and ATP content in lenses of hereditary cataract UPL rats.
2004 Apr 15
Disulfiram-induced fulminant hepatic failure in an active duty soldier.
2004 Aug
[Anterior myocardial infarction in a chronic alcoholic man on disulfiram therapy: a case report].
2004 Dec
Ethnic differences in substance abuse treatment retention, compliance, and outcome from two clinical trials.
2004 Feb
Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial.
2004 Mar
The molecular basis of the action of disulfiram as a modulator of the multidrug resistance-linked ATP binding cassette transporters MDR1 (ABCB1) and MRP1 (ABCC1).
2004 Mar
Accumulation of phenyl boronic acid-carrying telomers on a gold surface.
2004 May 1
One-pot synthesis of high-quality zinc-blende CdS nanocrystals.
2004 Nov 10
Disulfiram inhibits activating transcription factor/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease.
2004 Sep
Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells.
2005
Effect of inducers of DT-diaphorase on the haemolytic activity and nephrotoxicity of 2-amino-1,4-naphthoquinone in rats.
2005 Aug 15
Are alcoholism treatments effective? The Project MATCH data.
2005 Jul 14
Effects of dopamine beta-hydroxylase genotype and disulfiram inhibition on catecholamine homeostasis in mice.
2005 Nov
Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden.
2005 Sep
Cross-reactivity between thiurams.
2006 Mar
Antabuse reaction with ceftin.
2006 Nov
[Optic neuropathy while taking disulfiram].
2006 Oct
Disulfiram-induced transient optic and peripheral neuropathy: a case report.
2007 Dec
Refractive hypotension in a patient with disulfiram-ethanol reaction.
2007 Jan
Pharmacological profiling of disulfiram using human tumor cell lines and human tumor cells from patients.
2007 Jan 1
Perturbation of retinoic acid (RA)-mediated limb development suggests a role for diminished RA signaling in the teratogenesis of ethanol.
2007 Sep
Manic episode with psychosis following a lower than recommended dosage regimen of disulfiram.
2008 Jan 1
Patents

Patents

05374658
2
07858785
7
JP1090105A
1
JP2005508842A
12
JP2007099950A
2
JPH11335203A
1
JPS06490105A
1
JPS56143232A
1
JPS61296018A
1
JPS6490105A
1

Sample Use Guides

In Vivo Use Guide
Usual Adult Dose for Alcohol Dependence -Initial dose: 500 mg orally once a day (this dose is generally continued for the first 1 to 2 weeks) -Maintenance dose: 250 mg orally once a day (range: 125 mg to 500 mg once a day) Maximum dose: 500 mg once a day -Duration of therapy: Depending on the individual, therapy may last months or even years
Route of Administration: Oral
In Vitro Use Guide
Application of 1mM disulfiram to R. jostii RHA1, gave rise to 4-carboxymuconolactone on the β-ketoadipate pathway
Name Type Language
DISULFIRAM
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN  
Official Name English
ORA102
Code English
ANTABUSE
Brand Name English
DISULFIRAM [HSDB]
Common Name English
THIOPEROXYDICARBONIC DIAMIDE ((H2N)C(S))(SUB 2) S(SUB 2), TETRAETHYL-
Common Name English
TETRAETHYLTHIOPEROXYDICARBONIC DIAMIDE ((((C(SUB 2)H(SUB 5))(SUB 2)N)C(S))(SUB 2)S(SUB 2))
Common Name English
DISULFIRAM [MART.]
Common Name English
DISULFIRAM [MI]
Common Name English
Disulfiram [WHO-DD]
Common Name English
ORA-102
Code English
NSC-25953
Code English
DISULFIRAM [JAN]
Common Name English
disulfiram [INN]
Common Name English
TETRAETHYLTHIURAM DISULPHIDE
Systematic Name English
DISULFIRAM [EP IMPURITY]
Common Name English
DISULFIRAM [VANDF]
Common Name English
BIS(DIETHYLTHIOCARBAMOYL) DISULPHIDE
Systematic Name English
TETRAETHYLTHIURAM DISULFIDE
Systematic Name English
DISULFIRAM [ORANGE BOOK]
Common Name English
DISULFIRAM [IARC]
Common Name English
DISULFIRAM [USP MONOGRAPH]
Common Name English
Bis(diethylthiocarbamoyl) disulfide
Systematic Name English
DISULFIRAM [EP MONOGRAPH]
Common Name English
Classification Tree Code System Code
WHO-VATC QN07BB01
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
WHO-ATC P03AA04
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
FDA ORPHAN DRUG 522516
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
WHO-ATC N07BB01
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
NCI_THESAURUS C2160
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
LIVERTOX NBK548103
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
NDF-RT N0000175679
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
NCI_THESAURUS C1744
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
WHO-ATC P03AA54
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
NDF-RT N0000000183
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
FDA ORPHAN DRUG 771520
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
NCI_THESAURUS C1742
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
Code System Code Type Description
ECHA (EC/EINECS)
202-607-8
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
ChEMBL
CHEMBL964
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
CAS
97-77-8
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
DRUG BANK
DB00822
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
RS_ITEM_NUM
1224008
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
DAILYMED
TR3MLJ1UAI
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
MERCK INDEX
M4677
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY Merck Index
IUPHAR
7168
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
WIKIPEDIA
DISULFIRAM
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
INN
1781
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
DRUG CENTRAL
928
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
RXCUI
3554
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY RxNorm
EVMPD
SUB06326MIG
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
CHEBI
4659
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
NCI_THESAURUS
C447
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
EPA CompTox
DTXSID1021322
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
NSC
25953
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
MESH
D004221
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
FDA UNII
TR3MLJ1UAI
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
ALANWOOD
disulfiram
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
PUBCHEM
3117
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
HSDB
3317
Created by admin on Fri Dec 16 15:54:38 UTC 2022 , Edited by admin on Fri Dec 16 15:54:38 UTC 2022
PRIMARY
METABOLITE (PARENT)
Structure of DITIOCARB
SUBSTANCE RECORD
Structure of DISULFIRAM
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966